Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSAltenusin is a polyphenol fungal metabolite originally isolated from the fungus Alternaria that has diverse biological activities.1,2 It inhibits Src kinase with an IC50 value of 20 nM.3 Altenusin inhibits fibrillization of recombinant tau fragments in vitro and phosphorylation of tau in SH-SY5Y cells expressing human P301L mutant tau when used at a concentration of 10 μM.1 It is an agonist of the farnesoid X receptor (FXR; EC50 = 3.2 μM) that reduces blood glucose, serum insulin, and serum cholesterol levels, as well as hepatic lipogenic gene expression and steatosis, in a high fat diet-induced mouse model of obesity when administered at 30 mg/kg per day.2 Altenusin also has antioxidant and antifungal properties.
WARNING This product is not for human or veterinary use.
1. The polyphenol altenusin inhibits in vitro fibrillization of tau and reduces induced tau pathology in primary neurons. ACS Chem. Neurosci. 8(4), 743-751 (2017).
2. Altenusin, a nonsteroidal microbial metabolite, attenuates nonalcoholic fatty liver disease by activating the farnesoid X receptor. Mol. Pharmacol. 92(4), 425-436 (2017).
3. Fungal metabolites as potent protein kinase inhibitors: Identification of a novel metabolite and novel activities of known metabolites. Lett. Drug. Des. Discov. 100(1), 24-29 (2004).